KLF2/4 Antikörper (AA 415-513)
-
- Target Alle KLF2/4 Produkte
- KLF2/4 (Kruppel-Like Factor 2/4 (KLF2/4))
- Bindungsspezifität
- AA 415-513
- Reaktivität
- Human, Maus, Ratte
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser KLF2/4 Antikörper ist unkonjugiert
- Applikation
- Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Spezifität
- This antibody may crossreact with KLF2 due to high sequence similarity.
- Kreuzreaktivität
- Human, Maus, Ratte
- Homologie
- Cow,Sheep,Pig,Horse,Chicken,Guinea Pig
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human KLF4
- Isotyp
- IgG
-
-
- Applikationshinweise
-
WB 1:300-5000
ELISA 1:500-1000
FCM 1:20-100
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- Haltbarkeit
- 12 months
-
-
Pedicled no-touch saphenous vein graft harvest limits vascular smooth muscle cell activation: the PATENT saphenous vein graft study." in: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 45, Issue 4, pp. 717-25, (2014) (PubMed).
: "Pluripotent state induction in mouse embryonic fibroblast using mRNAs of reprogramming factors." in: International journal of molecular sciences, Vol. 15, Issue 12, pp. 21840-64, (2014) (PubMed).
: "MicroRNA-145 targeted therapy reduces atherosclerosis." in: Circulation, Vol. 126, Issue 11 Suppl 1, pp. S81-90, (2012) (PubMed).
: "
-
Pedicled no-touch saphenous vein graft harvest limits vascular smooth muscle cell activation: the PATENT saphenous vein graft study." in: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 45, Issue 4, pp. 717-25, (2014) (PubMed).
-
- Target
- KLF2/4 (Kruppel-Like Factor 2/4 (KLF2/4))
- Abstract
- KLF2/4 Produkte
- Hintergrund
-
Synonyms: EZF, GKLF, Krueppel-like factor 4, Epithelial zinc finger protein EZF, Gut-enriched krueppel-like factor, KLF4
Background: Transcription factor, can act both as activator and as repressor. Binds the 5'-CACCC-3' core sequence. Binds to the promoter region of its own gene and can activate its own transcription. Regulates the expression of key transcription factors during embryonic development. Plays an important role in maintaining embryonic stem cells, and in preventing their differentiation. Required for establishing the barrier function of the skin and for postnatal maturation and maintenance of the ocular surface. Involved in the differentiation of epithelial cells and may also function in skeletal and kidney development. Contributes to the down-regulation of p53/TP53 transcription.
- Gen-ID
- 9314
- UniProt
- O43474
-